Novel HPK1 Inhibitor Enters First-in-Human Trial for Advanced Solid Tumors
Researchers have initiated a first-in-human clinical trial of SWA1211, a novel inhibitor targeting hematopoietic progenitor kinase 1 (HPK1) for patients with advanced solid tumors. The Phase I study will evaluate the safety, tolerability, and preliminary anti-tumor activity of the investigational drug across multiple clinical sites in China.
The open-label, multi-center trial will employ a standard dose-escalation design, initially focusing on establishing a safe dosing range before expanding to explore potential therapeutic signals. Planned enrollment includes 60 patients aged 18-75 with advanced solid tumors who have exhausted standard treatment options. Collaborating institutions include Shanghai East Hospital, Zhejiang Cancer Hospital, and Shanghai Cancer Centre, suggesting a coordinated approach to early-stage drug development.
Research Context
SWA1211 represents an emerging approach to targeting HPK1, a kinase involved in T-cell activation and potential tumor suppression. Preclinical research has highlighted the molecule's potential to modulate immune response and potentially inhibit tumor progression through novel mechanistic pathways.